Condition
Schwannomatosis
Total Trials
5
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Completed2
Recruiting2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05684692Phase 2RecruitingPrimary
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
NCT03406208Not ApplicableCompleted
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
NCT04163419Phase 2Active Not RecruitingPrimary
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
NCT01885767Recruiting
Neurofibromatosis (NF) Registry Portal
NCT02298270Not ApplicableCompleted
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Showing all 5 trials